[vc_row full_width=”stretch_row_content_no_spaces” equal_height=”yes” content_placement=”bottom” css=”.vc_custom_1599596443343{margin-top: 0px !important;border-bottom-width: 4px !important;padding-top: 0px !important;padding-right: 20px !important;padding-bottom: 0px !important;padding-left: 20px !important;background-color: #f2f2f2 !important;border-bottom-color: #2c5d73 !important;border-bottom-style: solid !important;}”][vc_column width=”2\/3″ css=”.vc_custom_1599246783777{margin-top: 0px !important;padding-right: 20px !important;padding-left: 10px !important;}”][vc_custom_heading text=”Prevention and Treatment of Venous Thromboembolism Key Clinical Questions” font_container=”tag:h2|text_align:left|color:%23f7941d” use_theme_fonts=”yes” css=”.vc_custom_1599246800058{margin-top: 0px !important;padding-top: 40px !important;}”][\/vc_column][vc_column width=”1\/3″][vc_column_text]<\/p>\n
Home<\/a> \/ VTE Overview<\/a> \/ VTE Clinical Questions<\/a><\/p>\n [\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=”stretch_row_content_no_spaces” gap=”20″][vc_column width=”3\/4″ css=”.vc_custom_1599593943456{padding: 20px !important;}”][vc_custom_heading source=”post_title” use_theme_fonts=”yes”][vc_column_text]<\/p>\n Seven (33%) of institutions comment on how to manage the anticoagulants of patients who are on chronic therapeutic anticoagulation. All 7 recommend continuation of therapeutic anticoagulation, but there was some variability in what agents should be used\/continued when the guidance commented on this. Two (9.5%) recommended continuation of home DOAC therapy, with conversion to either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) if the patient deteriorates. Two (9.5%) recommend converting DOAC therapy to LMWH upon admission to the hospital.[\/vc_column_text][vc_row_inner gap=”30″ css=”.vc_custom_1599593972336{padding-right: 20px !important;padding-left: 20px !important;}”][vc_column_inner width=”1\/2″][vc_column_text]<\/p>\n The literature to date indicates that inpatients with COVID-19 infection appear to have a heightened risk of VTE as mentioned above. Further, some data indicate an increased risk of VTE associated with elevated D-dimer levels in COVID-19 patients. Since patients on therapeutic anticoagulation for a pre-existing thromboembolic event or risk are likely at heightened risk for nosocomial VTE, the additional risk of VTE from COVID-19, especially in the presence of elevated D-dimer levels, only increases the necessity to continue anticoagulation in this population.[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text]<\/p>\n It is uncertain what level of D-dimer elevation should warrant heightened concern for development of VTE. The effect of therapeutic anticoagulation on patients with COVID-19 is still ill-defined, nor is there certainty as to whether DOAC, UFH, and LMWH all have similar effects on the course of COVID-19.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][vc_column width=”1\/4″ css=”.vc_custom_1600126998229{border-top-width: 1px !important;border-right-width: 1px !important;border-bottom-width: 1px !important;border-left-width: 4px !important;padding-top: 20px !important;padding-right: 20px !important;padding-bottom: 20px !important;padding-left: 20px !important;border-left-color: #2c5d73 !important;border-left-style: solid !important;border-right-color: #2c5d73 !important;border-right-style: solid !important;border-top-color: #2c5d73 !important;border-top-style: solid !important;border-bottom-color: #2c5d73 !important;border-bottom-style: solid !important;}”][vc_raw_html]JTVCdWx0aW1hdGVfcG9zdF9saXN0JTIwaWQlM0QlMjIxMjQlMjIlNUQ=[\/vc_raw_html][vc_wp_custommenu nav_menu=”3″ title=”VTE Links” el_class=”subNavButton”][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":" The literature to date indicates that inpatients with COVID-19 infection appear to have a heightened risk of VTE as mentioned above….<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"_links":{"self":[{"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/posts\/166"}],"collection":[{"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/comments?post=166"}],"version-history":[{"count":11,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/posts\/166\/revisions"}],"predecessor-version":[{"id":629,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/posts\/166\/revisions\/629"}],"wp:attachment":[{"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/media?parent=166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/categories?post=166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hospitalinnovate.org\/covid19\/wp-json\/wp\/v2\/tags?post=166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}a. HOMERuN institutions<\/strong><\/h3>\n
b. What is Known<\/strong><\/h3>\n
c. What is Not Known<\/strong><\/h3>\n